DARE Dare Bioscience, Inc.
$0.66▲ +2.98%
Healthcare
Other
After hours
$0.69▲ +3.45%
Oct 27, 4:44 PM ET
Volume 51.6K
Avg Volume (10D) 128.0K
Key Metrics & Fundamentals
Market Cap
$13.04M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.63 - 3.78
% vs 50 MA
-12.36%
% vs 200 MA
-58.55%
RSI-14
33.4
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.14
Free Cash Flow
-$6.86M
Gross Rev
$187,546
Gross Profit
-$132,343
EBITDA
-$2.40M
COGS
$319,889
Operating Exp
$2.84M
Operating Income
-$2.97M
EBIT
-$2.97M
Pretax Income
-$2.98M
Net Income
-$2.98M
EPS (Diluted)
-0.20
Price & Volume History
Loading chart…
Recent News
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
GlobeNewswire · Oct 26, 2026 8:32 AM ET
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
GlobeNewswire · Oct 19, 2026 8:56 AM ET
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
GlobeNewswire · Oct 13, 2026 9:15 AM ET
Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
GlobeNewswire · Oct 8, 2026 9:15 AM ET
Dare Bioscience stock rises after receiving HPV treatment patent
Investing.com · Sep 28, 2026 10:32 AM ET
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
GlobeNewswire · Sep 28, 2026 8:20 AM ET
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
GlobeNewswire · Sep 14, 2026 8:50 AM ET
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
GlobeNewswire · Sep 11, 2026 6:55 AM ET
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
GlobeNewswire · Aug 31, 2026 8:44 AM ET
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
GlobeNewswire · Aug 27, 2026 9:01 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See DARE's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.